Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AdaptHealth (AHCO) Short term Debt (2018 - 2026)

AdaptHealth has reported Short term Debt over the past 8 years, most recently at $20.3 million for Q4 2025.

  • For Q4 2025, Short term Debt rose 25.0% year-over-year to $20.3 million; the TTM value through Dec 2025 reached $20.3 million, up 25.0%, while the annual FY2025 figure was $20.3 million, 25.0% up from the prior year.
  • Short term Debt for Q4 2025 was $20.3 million at AdaptHealth, up from $16.2 million in the prior quarter.
  • Over five years, Short term Debt peaked at $96.8 million in Q2 2021 and troughed at $16.2 million in Q3 2024.
  • A 5-year average of $31.0 million and a median of $22.7 million in 2022 define the central range for Short term Debt.
  • Biggest five-year swings in Short term Debt: soared 3644.2% in 2021 and later tumbled 74.16% in 2022.
  • Year by year, Short term Debt stood at $20.0 million in 2021, then skyrocketed by 75.0% to $35.0 million in 2022, then surged by 52.48% to $53.4 million in 2023, then plummeted by 69.55% to $16.2 million in 2024, then rose by 25.0% to $20.3 million in 2025.
  • Business Quant data shows Short term Debt for AHCO at $20.3 million in Q4 2025, $16.2 million in Q3 2025, and $16.2 million in Q2 2025.